These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22018846)

  • 21. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
    Kindelberger DW; Lee Y; Miron A; Hirsch MS; Feltmate C; Medeiros F; Callahan MJ; Garner EO; Gordon RW; Birch C; Berkowitz RS; Muto MG; Crum CP
    Am J Surg Pathol; 2007 Feb; 31(2):161-9. PubMed ID: 17255760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
    Lheureux S; Shaw PA; Karakasis K; Oza AM
    Gynecol Oncol; 2015 Aug; 138(2):235-7. PubMed ID: 26072440
    [No Abstract]   [Full Text] [Related]  

  • 23. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.
    Carlson JW; Jarboe EA; Kindelberger D; Nucci MR; Hirsch MS; Crum CP
    Int J Gynecol Pathol; 2010 Jul; 29(4):310-4. PubMed ID: 20567141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.
    Chene G; Rahimi K; Mes-Masson AM; Provencher D
    J Minim Invasive Gynecol; 2013; 20(2):153-9. PubMed ID: 23332575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
    Schlosshauer PW; Cohen CJ; Penault-Llorca F; Miranda CR; Bignon YJ; Dauplat J; Deligdisch L
    Cancer; 2003 Dec; 98(12):2599-606. PubMed ID: 14669279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fallopian tube: the dark face of pelvic carcinogenesis].
    Watkin E; Devouassoux-Shisheboran M
    Ann Pathol; 2011 Oct; 31(5):345-52. PubMed ID: 21982240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
    Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis.
    Herrington CS; McCluggage WG
    J Pathol; 2010 Jan; 220(1):5-6. PubMed ID: 19882674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serous carcinogenesis in the fallopian tube: a descriptive classification.
    Jarboe E; Folkins A; Nucci MR; Kindelberger D; Drapkin R; Miron A; Lee Y; Crum CP
    Int J Gynecol Pathol; 2008 Jan; 27(1):1-9. PubMed ID: 18156967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Morphologic and immunohistochemical features of Fallopian tubes and ovaries in women with genetic predisposition to ovarian cancer].
    Bilyk EA; Buchanskaia LG; Polishchuk LZ; Peëvich T
    Vopr Onkol; 2012; 58(4):507-13. PubMed ID: 23607206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinoma.
    Chene G; Cayre A; Raoelfils I; Lagarde N; Dauplat J; Penault-Llorca F
    Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():89-95. PubMed ID: 25461359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
    Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
    Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
    Kerner R; Sabo E; Gershoni-Baruch R; Beck D; Ben-Izhak O
    Gynecol Oncol; 2005 Nov; 99(2):367-75. PubMed ID: 16051332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?
    Cass I; Walts A; Karlan BY
    Gynecol Oncol; 2010 Apr; 117(1):27-31. PubMed ID: 20110118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls.
    Mehra KK; Chang MC; Folkins AK; Raho CJ; Lima JF; Yuan L; Mehrad M; Tworoger SS; Crum CP; Saleemuddin A
    Mod Pathol; 2011 Jan; 24(1):152-6. PubMed ID: 20871594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
    J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serous tubal intraepithelial carcinoma arising from the intrauterine portion of the fallopian tube after bilateral salpingo-oophorectomy.
    Yoshida H; Shintani D; Imai Y; Fujiwara K
    Eur J Gynaecol Oncol; 2016; 37(3):404-6. PubMed ID: 27352575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    Anton A; Schott S; Kaip G; Rath M; Heil J; Aulmann S; Sinn HP
    Arch Gynecol Obstet; 2014 May; 289(5):1079-85. PubMed ID: 24196303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.